Q1 Earnings Estimate for IONS Issued By HC Wainwright

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued on Monday, April 7th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($1.04) for the quarter. HC Wainwright has a “Strong-Buy” rating and a $45.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.61) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.86) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm had revenue of $227.00 million during the quarter, compared to analysts’ expectations of $140.97 million. The firm’s revenue for the quarter was down 30.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.12 EPS.

Other equities analysts have also recently issued research reports about the company. Guggenheim restated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Thursday, April 3rd. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. decreased their price objective on shares of Ionis Pharmaceuticals from $47.00 to $45.00 and set a “neutral” rating for the company in a report on Monday, March 24th. BMO Capital Markets dropped their target price on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research note on Thursday, February 20th. Finally, Redburn Atlantic initiated coverage on shares of Ionis Pharmaceuticals in a research note on Monday, March 31st. They set a “neutral” rating and a $39.00 price target for the company. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $56.72.

Ionis Pharmaceuticals Trading Up 4.5 %

IONS opened at $27.90 on Thursday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The stock’s 50 day moving average price is $31.22 and its 200-day moving average price is $34.61. Ionis Pharmaceuticals has a one year low of $23.95 and a one year high of $52.34. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of -9.18 and a beta of 0.29.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of large investors have recently modified their holdings of IONS. Xponance Inc. boosted its stake in Ionis Pharmaceuticals by 1.7% in the 4th quarter. Xponance Inc. now owns 19,339 shares of the company’s stock worth $676,000 after purchasing an additional 318 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Ionis Pharmaceuticals by 3.4% during the fourth quarter. Amalgamated Bank now owns 10,292 shares of the company’s stock worth $360,000 after buying an additional 335 shares during the period. Vontobel Holding Ltd. grew its holdings in shares of Ionis Pharmaceuticals by 6.6% during the fourth quarter. Vontobel Holding Ltd. now owns 5,865 shares of the company’s stock valued at $205,000 after buying an additional 363 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Ionis Pharmaceuticals by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company’s stock valued at $763,000 after acquiring an additional 373 shares during the period. Finally, Treasurer of the State of North Carolina raised its stake in Ionis Pharmaceuticals by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 68,803 shares of the company’s stock worth $2,405,000 after acquiring an additional 440 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Eric Swayze sold 7,154 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the completion of the sale, the executive vice president now owns 45,670 shares of the company’s stock, valued at $1,499,802.80. This trade represents a 13.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Patrick R. O’neil sold 6,165 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares in the company, valued at approximately $1,816,632.24. This trade represents a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,956 shares of company stock worth $3,608,439. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.